Progressive Systemic Sclerosis (Scleroderma)
Theodore B. Bayles
Abstract
Theodore B. Bayles
Abstract
The term “progressive systemic sclerosis” is preferred to “scleroderma,” since the skin is not always involved at first and rarely is not involved at all, even in fatal cases. Organic involvement is widespread. There is no satisfactory treatment, but there are measures which moderate the inexorable and fatal course of the disease, and certainly symptomatic relief can be provided. Corticosteroids cannot be endorsed as having a real place in therapy.
OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The term “progressive systemic sclerosis” is preferred to “scleroderma,” since the skin is not always involved at first and rarely is not involved at all, even in fatal cases. Organic involvement is widespread. There is no satisfactory treatment, but there are measures which moderate the inexorable and fatal course of the disease, and certainly symptomatic relief can be provided. Corticosteroids cannot be endorsed as having a real place in therapy.
Key concepts: Medicine, Scleroderma (fungus), Progressive systemic sclerosis, Dermatology, Disease, Systemic disease, Multiple sclerosis, Systemic therapy